- Home
- INVE vs SAVA Comparison
INVE vs SAVA Comparison
Compare INVE & SAVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INVE
- SAVA
- Stock Information
- Founded
- INVE 1990
- SAVA 1998
- Country
- INVE United States
- SAVA United States
- Employees
- INVE N/A
- SAVA N/A
- Industry
- INVE Computer peripheral equipment
- SAVA Biotechnology: Pharmaceutical Preparations
- Sector
- INVE Technology
- SAVA Health Care
- Exchange
- INVE Nasdaq
- SAVA Nasdaq
- Market Cap
- INVE 85.9M
- SAVA 102.4M
- IPO Year
- INVE 1997
- SAVA N/A
- Fundamental
- Price
- INVE $3.78
- SAVA $4.15
- Analyst Decision
- INVE Strong Buy
- SAVA Buy
- Analyst Count
- INVE 2
- SAVA 2
- Target Price
- INVE $5.50
- SAVA $5.00
- AVG Volume (30 Days)
- INVE 27.5K
- SAVA 5.3M
- Earning Date
- INVE 11-06-2025
- SAVA 11-06-2025
- Dividend Yield
- INVE N/A
- SAVA N/A
- EPS Growth
- INVE N/A
- SAVA N/A
- EPS
- INVE 3.12
- SAVA N/A
- Revenue
- INVE $23,538,000.00
- SAVA N/A
- Revenue This Year
- INVE N/A
- SAVA N/A
- Revenue Next Year
- INVE $9.06
- SAVA N/A
- P/E Ratio
- INVE $1.19
- SAVA N/A
- Revenue Growth
- INVE N/A
- SAVA N/A
- 52 Week Low
- INVE $2.86
- SAVA $1.15
- 52 Week High
- INVE $4.29
- SAVA $33.98
- Technical
- Relative Strength Index (RSI)
- INVE 56.76
- SAVA 74.49
- Support Level
- INVE $3.33
- SAVA $3.39
- Resistance Level
- INVE $3.80
- SAVA $3.84
- Average True Range (ATR)
- INVE 0.15
- SAVA 0.40
- MACD
- INVE 0.02
- SAVA 0.10
- Stochastic Oscillator
- INVE 91.53
- SAVA 94.30
About INVE Identiv Inc.
Identiv Inc is a security technology company. It secures and manages access to physical places, things, and information. The company has one reportable segment: the IoT Business segment. Geographically, it generates maximum revenue from the Americas and also has a presence in Europe and the Middle East, and Asia-Pacific.
About SAVA Cassava Sciences Inc.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.